 Proactive Investors USA & Canada | CTI launches Pixuvri in EU to treat adult patients with refractory aggressive ... pharmabiz.com The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have ... Cell Therapeutics shares surge on commercial launch of lymphoma drug in ... Before Jumping on the Cell Therapeutics (CTIC) Bandwagon (CELG, CTIC ... Cell Therapeutics initiates launch of Pixuvri in Europe |
